SAPPHIRE Study Expands With Inclusion of Ascension
Filed with ASX · · 3 pages · English
PERTH, Australia, 13 November 2025: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Ascension, one of the largest non-profit and Catholic health systems in the U.S., has agreed to participate in
In the deck
Earlier from Artrya
- Mass General Brigham to Participate in SAPPHIRE Study
- Completion of Placement and Cleansing Notice
- Completion of Share Purchase Plan
- Successful A$75 million placement and launch of SPP
- Trading Halt
Later from Artrya
- S&P DJI Announces December 2025 Quarterly Rebalance
- Second US Commercial Customer - Northeast Georgia
- First Revenues from Salix Coronary Plaque Module
- Cone Health Becomes Third U.S. Customer
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Artrya into a list and get an email when it puts out news.
Follow Artrya